Structure Therapeutics
GPCR
192 hedge funds and large institutions have $3.62B invested in Structure Therapeutics in 2026 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 75 increasing their positions, 51 reducing their positions, and 31 closing their positions.
164% more call options, than puts
Call options by funds: $25.6M | Put options by funds: $9.71M
50% more funds holding in top 10
Funds holding in top 10: 6 → 9 (+3)
47% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 51
12% more capital invested
Capital invested by funds: $3.22B → $3.62B (+$401M)
0.88% more ownership
Funds ownership: 94.18% → 95.05% (+0.88%)
6% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 31
2% less funds holding
Funds holding: 196 → 192 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$71.1M |
| 2 |
O
OrbiMed
New York
|
+$32.5M |
| 3 |
Morgan Stanley
New York
|
+$22.2M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$20.4M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$14.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$51.1M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$26.3M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$26.2M |
| 4 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$20.2M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$14.7M |
GPCR Hedge Fund Activity: Q2 2026 in Review
192 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Structure Therapeutics (GPCR) for Q2 2026, worth a combined $3.62B — up 12% from $3.22B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of GPCR and 29 opened new positions — a net loss of 2 holders — while 51 trimmed existing stakes and 75 added.
The largest buyer was RTW Investments, opening a new position worth an estimated $71.1M. The largest seller was T. Rowe Price Associates, cutting an estimated $51.1M.
- 192 institutional investors held Structure Therapeutics (GPCR) as of Q2 2026, down from 196 in Q1 2026.
- Funds reported $3.62B of Structure Therapeutics stock for Q2 2026, up 12% quarter-over-quarter.
- 29 funds opened new Structure Therapeutics positions in Q2 2026 and 31 closed out, a net change of -2 holders.
- The largest Structure Therapeutics buyer in Q2 2026 was RTW Investments, an estimated $71.1M added.
- The largest Structure Therapeutics seller in Q2 2026 was T. Rowe Price Associates, an estimated $51.1M sold.
Based on aggregated 13F filings for Q2 2026.